Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude Ph2 NKT2152 avec palbociclib et sasanlimab chez des sujets atteints d'un carcinome rénal à cellules claires avancé (ccRcc)

9 novembre 2026 mis à jour par: NiKang Therapeutics, Inc.

Un essai de phase 2 pour évaluer l'innocuité et l'efficacité du NKT2152 en association avec le palbociclib (doublet) et avec le palbociclib et le sasanlimab (triplet) chez des sujets atteints d'un carcinome rénal à cellules claires avancé ou métastatique

The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.

Aperçu de l'étude

Description détaillée

This is a Phase 2 open-label, multicenter, global study of NKT2152. This study is designed as two phases: a Lead-in phase and an Expansion phase. Patients must be 18 years or older, with advanced or metastatic clear cell renal cell carcinoma (ccRCC). Eligible patients must have progressed or relapsed after at least 1 prior anti-vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) systemic therapy and 1 immune checkpoint inhibitor (ICI) for advanced or metastatic ccRCC alone or in combination.

The Lead-in phase is designed as a dose escalation phase to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib and sasanlimab in advanced or metastatic ccRCC patients who received prior therapy.

The subsequent Expansion phase will evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib and sasanlimab in advanced or metastatic ccRCC patients who received prior therapy.

Type d'étude

Interventionnel

Inscription (Réel)

18

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • California
      • La Jolla, California, États-Unis, 92093
        • University of California San Diego
    • Illinois
      • Chicago, Illinois, États-Unis, 60611
        • Northwestern University - Feinberg School of Medicine
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • University of Michigan-Rogel Cancer Center
    • Nebraska
      • Omaha, Nebraska, États-Unis, 68130
        • Nebraska Cancer Specialists
    • New York
      • New York, New York, États-Unis, 10065-6094
        • Memorial Sloan Kettering Cancer Center
    • Texas
      • Dallas, Texas, États-Unis, 75390-9324
        • UT Southwestern Medical Center
    • Virginia
      • Charlottesville, Virginia, États-Unis, 22908
        • University of Virginia Health System

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Must have locally advanced or metastatic ccRCC and have progressed or relapsed after at least 1 prior anti-VEGF/VEGFR systemic therapy and 1 ICI.
  • Measurable disease per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
  • KPS score of at least 70%
  • Able to swallow oral medications.

Exclusion Criteria:

  • Active CNS metastases and/or carcinomatous meningitis
  • Has had any major cardiovascular event within 6 months or clinically significant cardiovascular disease
  • Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 3 months before administration of study drug.
  • Has known HIV
  • History of hepatitis B or known active hepatitis C infection
  • Has received prior treatment with NKT2152, other HIF2α inhibitors, other CDK 4/6 inhibitors, palbociclib, or sasanlimab
  • Radiation therapy for bone metastasis within 2 weeks, or any other external radiation therapy within 4 weeks before administration of the first dose of study treatment
  • Corrected QT interval calculated by Fridericia formula (QTcF) > 480 ms within 28 days prior to first dose
  • Hypoxia or requires intermittent or chronic supplemental oxygen or any chronic lung condition which has required supplemental oxygen in the past
  • Has a history of interstitial lung disease
  • Has any active or recent history of a known or suspected autoimmune disease

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Lead-in Doublet combination

Lead-in Doublet assesses safety of oral dosing NKT2152 at increasing dosage levels in combination with palbociclib to determine a recommended dose for expansion (RDE).

Oral HIF2a inhibitor

a cyclin-dependent kinases (CDK) 4 and 6 inhibitor

Autres noms:
  • IBRANCE®
Expérimental: Lead-in Triplet combination

Lead-in Triplet assesses the safety of two doses of NKT2152 identified in the Doublet arm (RDE and RDE-1) by orally dosing ccRCC patients with NKT2152 in combination with palbociclib and sasanlimab

Oral HIF2a inhibitor

a cyclin-dependent kinases (CDK) 4 and 6 inhibitor

Autres noms:
  • IBRANCE®

an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration

Expérimental: Expansion Doublet combination

Subjects randomized to Arm 1 will receive the Doublet combination (NKT2152 in combination with palbociclib) to provide an assessment of anti-tumor activity and to determine the RP2D.

Oral HIF2a inhibitor

a cyclin-dependent kinases (CDK) 4 and 6 inhibitor

Autres noms:
  • IBRANCE®
Expérimental: Expansion Triplet combination

Subjects randomized to Arm 2 will receive the Triplet therapy (NKT2152 in combination with palbociclib and sasanlimab) to provide an assessment of anti-tumor activity and to determine the RP2D.

Oral HIF2a inhibitor

a cyclin-dependent kinases (CDK) 4 and 6 inhibitor

Autres noms:
  • IBRANCE®

an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants With Dose Limiting Toxicity (DLT) Events During the DLT Monitoring Period (First 28 Days of Dosing) in the Lead-in Phase
Délai: 28 days

Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period.

DLTs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 .0.

28 days
Objective Response Rate (ORR) Determined by the Investigator
Délai: 1 years

ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

1 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Progression-free Survival (PFS)
Délai: 2 years

PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression or death.

2 years
Duration of Response (DOR)
Délai: 1 years

Duration of overall response is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first.

1 years
Time to Response (TTR)
Délai: 1 years

TTR is defined as the time from first dose to the first documented CR or PR which is subsequently confirmed.

1 years
Overall Survival (OS)
Délai: 2 years

OS defined as the time from the date the participant started study drug to death for any reason.

2 years
Clinical Benefit Rate (CBR)
Délai: 1 years

CBR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) or a stable disease (SD) of 8 weeks or longer based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

1 years
Number of Participants With Adverse Events
Délai: 2 years

An adverse event (AE) is defined as any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.

2 years
Maximum Observed Plasma Concentration (Cmax) of NKT2152
Délai: C1D1 (1-24hr post-dose)

Maximum observed plasma concentration (Cmax) of NKT2152 on C1D1 (1, 2, 4, 6, and 24 hours post-dose)

C1D1 (1-24hr post-dose)
Time to Maximum Observed Plasma Concentration of NKT2152 (Tmax)
Délai: C1D1 (1-24hr post-dose)

Time to maximum observed plasma concentration of NKT2152 (Tmax) on C1D1

C1D1 (1-24hr post-dose)
Observed Trough Concentration of NKT2152 (Ctrough)
Délai: C1D1 (1-24hr post-dose)

Observed trough concentration of NKT2152 (Ctrough) for single dose (1, 2, 4, 6, and 24 hours post-dose)

C1D1 (1-24hr post-dose)
Area Under the Plasma Concentration Time Curve (AUC0-t) of NKT2152
Délai: C1D1 and C1D8 (0-24hr post-dose)

Area under the plasma concentration time curve (AUC0-t) of NKT2152 at C1D1 (1, 2, 4, 6, and 24 hours post-dose) and C1D8 (pre-dose, 1, 2, 4, 6, and 24 hours post-dose)

C1D1 and C1D8 (0-24hr post-dose)
Accumulation Ratio of NKT2152 (RAC)
Délai: C1D1 and C1D8 (0-24hr post-dose)

Accumulation Ratio of NKT2152 (RAC) calculated as C1D8 AUC0-t divided by C1D1 AUC0-t

C1D1 and C1D8 (0-24hr post-dose)
Maximum Observed Plasma Concentration (Cmax) of Palbociclib
Délai: C1D1 (1-24hr post-dose)

Maximum observed plasma concentration (Cmax) of palbociclib on C1D1 (1, 2, 4, 6, and 24 hours post-dose)

C1D1 (1-24hr post-dose)
Time to Maximum Observed Plasma Concentration of Palbociclib (Tmax)
Délai: C1D1 (1-24 hr post-dose)

Time to maximum observed plasma concentration of palbociclib (Tmax) on C1D1 (1, 2, 4, 6, and 24 hours post-dose)

C1D1 (1-24 hr post-dose)
Observed Trough Concentration of Palbociclib (Ctrough)
Délai: C1D1 (1-24 hr post-dose)

Observed trough concentration of palbociclib (Ctrough) on C1D1 (1, 2, 4, 6, and 24 hours post-dose)

C1D1 (1-24 hr post-dose)
Area Under the Plasma Concentration Time Curve (AUC0-t) of Palbociclib
Délai: C1D1 and C1D15 (0-24hr post-dose)

Area under the plasma concentration time curve (AUC0-t) of palbociclib at C1D1 (1, 2, 4, 6, and 24 hours post-dose) and C1D15 (pre-dose, 1, 2, 4, 6, and 24 hours post-dose)

C1D1 and C1D15 (0-24hr post-dose)
Accumulation Ratio of Palbociclib (RAC)
Délai: C1D1 and C1D15 (0-24hr post-dose)

Accumulation Ratio of palbociclib (RAC) calculated as C1D15 AUC0-t divided by C1D1 AUC0-t

C1D1 and C1D15 (0-24hr post-dose)
Observed Trough Concentration of Sasanlimab (Ctrough)
Délai: 1 years

Observed trough concentration of sasanlimab (Ctrough)

1 years
Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
Délai: 1 years

Maximum observed plasma concentration (Cmax) of sasanlimab

1 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

28 juillet 2023

Achèvement primaire (Réel)

30 juin 2025

Achèvement de l'étude (Réel)

4 septembre 2025

Dates d'inscription aux études

Première soumission

29 juin 2023

Première soumission répondant aux critères de contrôle qualité

6 juillet 2023

Première publication (Réel)

7 juillet 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

IPD are not planned to be shared at this time

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner